

| | | | | | |
|--|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449/PTO (Revised 07/2007) | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/578,590 |
| | | | | Filing Date | (I.A.) November 4, 2004 |
| | | | | First Named Inventor | Long |
| | | | | Art Unit | 1643 |
| | | | | Examiner Name | <i>Not Yet Assigned</i> |
| Sheet | 1 | of | 2 | Attorney Docket Number | 035784/311260 |

| U. S. PATENT DOCUMENTS | | | | | |
|-------------------------------|----------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. | Document Number Number - Kind Code (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear |
| | 13 | US-5,397,703 | 03-14-1995 | de Boer <i>et al.</i> | |
| | 14 | US-5,677,165 | 10-14-1997 | de Boer <i>et al.</i> | |
| | 15 | US-5,874,082 | 02-23-1999 | de Boer | |
| | 16 | US-6,004,552 | 12-21-1999 | de Boer <i>et al.</i> | |
| | 17 | US-6,056,959 | 05-02-2000 | de Boer <i>et al.</i> | |
| | 18 | US-6,315,998 B1 | 11-13-2001 | de Boer <i>et al.</i> | |
| | 19 | US-6,899,879 B2 | 05-31-2005 | de Boer <i>et al.</i> | |
| | 20 | US-20070098717 A1 | 05-03-2007 | Long <i>et al.</i> | |
| | 21 | US-20070098718 A1 | 05-03-2007 | Long <i>et al.</i> | |
| | 22 | US-20070110754 A1 | 05-17-2007 | Long <i>et al.</i> | |
| | 23 | US-20070218060 A1 | 09-20-2007 | Long <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|---------------------------------|----------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. | Foreign Patent Document Country Code - Number Kind Code (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | 24 | WO 94/01547 A3 | 01-20-1994 | Cetus Oncology Corporation | |
| | 25 | WO 95/17202 A1 | 06-29-1995 | Immunex Corporation | |
| | 26 | WO 96/18413 A1 | 06-20-1996 | The University of Birmingham | |
| | 27 | WO 97/31025 A1 | 08-28-1997 | Chiron Corporation | |
| | 28 | WO 99/42075 A2 | 08-26-1999 | Bristol-Myers Squibb Company | |
| | 29 | WO 02/028481 A2 | 04-11-2002 | Chiron Corporation | |
| | 30 | WO 02/060485 A2 | 08-08-2002 | IDEC Pharmaceuticals Corporation | |

| | |
|--------------------|-----------------|
| Examiner Signature | Date Considered |
|--------------------|-----------------|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | | | | |
|--|---|----|---|--------------------------|-------------------------|
| Substitute for form 1449/PTO (Revised 07/2007) | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/578,590 |
| | | | | Filing Date | (I.A.) November 4, 2004 |
| | | | | First Named Inventor | Long |
| | | | | Art Unit | 1643 |
| | | | | Examiner Name | <i>Not Yet Assigned</i> |
| Sheet | 2 | of | 2 | Attorney Docket Number | 035784/311260 |

| FOREIGN PATENT DOCUMENTS | | | | | |
|---------------------------------|----|-------------------|------------|--------------------|--|
| | 31 | WO 2005/044304 A2 | 05-19-2005 | Chiron Corporation | |
| | 32 | WO 2005/044305 A2 | 05-19-2005 | Chiron Corporation | |
| | 33 | WO 2005/044306 A2 | 05-19-2005 | Chiron Corporation | |
| | 34 | WO 2005/044307 A2 | 05-19-2005 | Chiron Corporation | |
| | 35 | WO 2005/044854 A2 | 05-19-2005 | Chiron Corporation | |
| | 36 | WO 2005/044855 A2 | 05-19-2005 | Chiron Corporation | |

| OTHER DOCUMENTS | | | | | |
|------------------------|----------|---|--|--|---------------------------------------|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | English Language Translation Attached |
| | 37 | BALINT, R., <i>et al.</i> , "Antibody Engineering by Parsimonious Mutagenesis," <i>Gene</i> , 1993, pp. 109-118, Vol. 137, No. 27. | | | |
| | 38 | ELLMARK, P., <i>et al.</i> , "Modulation of the CD40-CD40 Ligand Interaction Using Human Anti-CD40 Single-Chain Antibody Fragments Obtained from the n-CoDeR Phage Display Library," <i>Immunology</i> , 2002, pp. 456-463, Vol. | | | |
| | 39 | HAGER A-C MALMBORG, <i>et al.</i> , "Affinity and Epitope Profiling of Mouse Anti-CD40 Monoclonal Antibodies," <i>Scandinavian Journal of Immunology</i> , 2003, pp. 517-524, Vol. 57, No. 6. | | | |
| | 40 | LITTLE, M., <i>et al.</i> , "Of Mice and Men: Hybridoma and Recombinant Antibodies," <i>Review Immunology Today</i> , 2000, pp. 364-370, Vol. 21. | | | |
| | 41 | TAI, Y., <i>et al.</i> , "Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications," <i>Cancer Research</i> , 2004, pp. 2846-2852, Vol. 64, No. 8. | | | |
| | 42 | WENG WEN-KAI, <i>et al.</i> , "Human Anti-CD40 Antagonistic Antibodies Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma," <i>Blood</i> , 2001, p. 466a, Vol. 98, No. 11, Part 1, Abstract #1947. | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.